Radical Clarity in Drug Pricing: How Rescription Uses the 340B Program and Patented Tech to Lower Costs

In this episode of Product in Healthtech, we reconnect with Scott Martin, founder and CEO of Rescription, to discover how his company has evolved since our previous conversation.

Topics covered:

• Rescription's "radical clarity" approach to transforming prescription drug costs
• How Rescription leverages the 340B federal program as intended to benefit both health systems and patients
• Results from partnerships with Bergen New Bridge and Baton Rouge General, showing 27-35% savings
• Why patients under Rescription's model receive zero-dollar copays for prescriptions
• The patent-pending adjudication technology developed with Vynyl that enables upfront processing at scale
• Rescription's ambitious expansion plans across 14 states and 15 additional health systems

Key moments:

• [01:16] Scott explains how Rescription's model differs from traditional PBMs
• [03:09] Clarifying misconceptions about the 340B program
• [05:14] Updates on partnerships with Bergen New Bridge and Baton Rouge General
• [07:25] How Rescription addresses pharmaceutical manufacturer pushback
• [09:24] Details on Rescription's patent-pending adjudication technology
• [11:15] Future expansion plans and new service offerings

Resources mentioned:

• Wall Street Journal article featuring Rescription (link to be added)

Follow Product in Healthtech:

• Website: productinhealthtech.com
• LinkedIn: Product in Healthtech
• Email: [email protected]

Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.